Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

• Status: RECRUITING
• Trial end date: 2027-06-06

Summary

The goal of this clinical trial is to learn ifDisitamab Vedotin in combination with tislelizumab and bevacizumab can treat in locally advanced or metastatic non-small cell lung cancer patients with HER2 mutation/amplification/expression. The main questions it aims to answer are:

1. objective response rate;

2. Progression-Free Survival;

3. Overall Survival;

4. Disease Control Rate;

5. Duration of Response.

• Phase: PHASE2

Details

• Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
• Treatments: Bevacizumab; disitamab vedotin; tislelizumab